William L Dahut Selected Research

VA 061 (VA061)

12/2008	Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
1/2008	A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
12/2007	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer.
8/2007	Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
3/2007	Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
1/2007	Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?
11/2005	Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.
10/2005	A phase II study of perifosine in androgen independent prostate cancer.
3/2005	A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
12/2004	Genotyping and functional analysis of the D104N variant of human endostatin.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

William L Dahut Research Topics

Disease

100	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 11/2002
41	Neoplasms (Cancer) 01/2022 - 01/2003
17	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2004
5	Carcinoma (Carcinomatosis) 11/2020 - 05/2008
5	Vaccinia 09/2013 - 05/2008
4	Disease Progression 01/2022 - 03/2007
4	Hypertension (High Blood Pressure) 06/2013 - 02/2007
4	Osteonecrosis (Kienbock's Disease) 11/2010 - 01/2007
3	Fowlpox 09/2013 - 05/2008
3	Renal Cell Carcinoma (Grawitz Tumor) 08/2011 - 11/2005
2	Circulating Neoplastic Cells 01/2021 - 01/2017
2	Fatigue 06/2013 - 10/2005
2	Multiple Myeloma 11/2010 - 01/2007
1	Overweight 04/2022
1	Cystitis 01/2022
1	Atherosclerotic Plaque (Atheroma) 01/2022
1	Residual Neoplasm 12/2021
1	Urogenital Neoplasms 01/2021
1	Thyroid Neoplasms (Thyroid Cancer) 01/2020
1	medullary Thyroid cancer 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2016
1	Insulin Resistance 08/2016
1	Erythema Multiforme 02/2016

Drug/Important Bio-Agent (IBA)

33	AndrogensIBA 01/2022 - 01/2003
17	Docetaxel (Taxotere)FDA Link 01/2021 - 01/2003
16	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 11/2005
14	VaccinesIBA 01/2020 - 08/2006
14	VA 061 (VA061)IBA 12/2008 - 01/2003
11	Thalidomide (Thalomid)FDA Link 04/2010 - 11/2002
9	Prednisone (Sone)FDA LinkGeneric 01/2021 - 01/2008
8	Bevacizumab (Avastin)FDA Link 10/2016 - 02/2007
8	Angiogenesis InhibitorsIBA 01/2014 - 02/2007
7	Testosterone (Sustanon)FDA Link 04/2022 - 02/2008
7	Pharmaceutical PreparationsIBA 01/2022 - 11/2004
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2013
7	Diphosphonates (Bisphosphonates)IBA 11/2010 - 01/2004
6	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 02/2008
6	PROSTVACIBA 01/2020 - 05/2012
6	Sorafenib (BAY 43-9006)FDA Link 02/2016 - 01/2008
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2010 - 02/2007
4	enzalutamideIBA 01/2022 - 01/2020
4	cabozantinibIBA 01/2021 - 02/2015
4	Cancer VaccinesIBA 01/2020 - 01/2010
4	Lenalidomide (CC 5013)FDA Link 10/2016 - 03/2004
4	Hormones (Hormone)IBA 03/2009 - 12/2003
3	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 07/2010
3	IpilimumabIBA 11/2020 - 05/2012
3	AntigensIBA 01/2020 - 01/2010
3	taxaneIBA 06/2011 - 01/2007
2	FluoridesIBA 01/2022 - 12/2018
2	CalciumIBA 01/2022 - 09/2007
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2004
2	olaparibIBA 12/2021 - 12/2018
2	durvalumabIBA 12/2021 - 12/2018
2	Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)IBA 01/2020 - 08/2007
2	EndoglinIBA 01/2017 - 10/2015
2	carotuximabIBA 01/2017 - 10/2015
2	Tyrosine Kinase InhibitorsIBA 02/2015 - 12/2014
2	cabazitaxel FDA Link 06/2011 - 03/2011
2	Ketoconazole (Nizoral)FDA LinkGeneric 06/2010 - 03/2005
2	Oxygen (Dioxygen)IBA 12/2009 - 11/2005
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 03/2009 - 05/2005
1	bicalutamide (Casodex)FDA LinkGeneric 04/2022
1	Metformin (Glucophage)FDA LinkGeneric 04/2022
1	Topoisomerase I InhibitorsIBA 01/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022
1	CamptothecinIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	IT-101IBA 01/2022
1	2- (3- (1- carboxy- 5- ((6- fluoropyridine- 3- carbonyl)amino)pentyl)ureido)pentanedioic acidIBA 01/2022
1	NivolumabIBA 11/2020
1	Technetium (Technetium 99m)IBA 11/2020
1	IodineIBA 01/2020
1	LyasesIBA 01/2020
1	CytochromesIBA 01/2020
1	Androgen Receptor AntagonistsIBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	PlatinumIBA 01/2020
1	seviteronelIBA 01/2020
1	Technetium Tc 99m MedronateIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2018
1	Sodium Fluoride (Ossin)FDA Link 08/2017
1	Monoclonal AntibodiesIBA 01/2017
1	OsteopontinIBA 01/2017
1	RadiopharmaceuticalsIBA 10/2016
1	DiaminesIBA 10/2016
1	Organophosphonates (Phosphonates)IBA 10/2016
1	samarium Sm-153 lexidronam (Quadramet)FDA Link 10/2016
1	ElementsIBA 08/2016
1	LipidsIBA 08/2016
1	Radium-223IBA 01/2016
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 02/2015
1	malic acid (malate)IBA 02/2015

Therapy/Procedure

43	Therapeutics 01/2022 - 05/2003
35	Castration 01/2022 - 04/2004
9	Drug Therapy (Chemotherapy) 01/2020 - 07/2004
6	Immunotherapy 01/2021 - 08/2006
6	Radiotherapy 01/2021 - 05/2003
4	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 01/2017
1	Aftercare (After-Treatment) 12/2021